Literature DB >> 7688292

Developmental expression of binding sites and messenger ribonucleic acid for vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis.

L B Jakeman1, M Armanini, H S Phillips, N Ferrara.   

Abstract

Vascular endothelial growth factor (VEGF) is an endothelial cell mitogen and angiogenic inducer produced by a variety of cell lines and tissues. As a soluble protein that exhibits a unique target cell specificity for vascular endothelial cells, VEGF has the potential to play an important role in the development of the vascular system. To better understand the role of VEGF in the processes of vasculogenesis and embryonic angiogenesis, patterns of mRNA expression and [125I]VEGF-binding sites were examined in sections of rat embryos and surrounding tissues during the early stages of development. In situ hybridization revealed the most intense hybridization of VEGF mRNA in the giant trophoblast cells and the mesometrium of early postimplantation specimens. In contrast, only low levels of expression were detected in the embryo until later in embryonic development. Possible embryonic targets for this secreted protein, as identified by displaceable [125I] VEGF binding, were found in association with the early egg sac at E8 and evident in hemangioblasts (blood islands) within the yolk sac at E8-E11. In addition, at all stages, binding was observed along the lumina of blood vessels, of both maternal and embryonic origin. These results provide evidence to support the hypothesis that VEGF plays an important role in the normal development of the embryo and supporting tissues. In the presence of ubiquitous and persistent high affinity binding sites on vascular endothelial cells and precursors, the growth of the vascular system may be regulated in early development by regional expression of VEGF by trophoblast and maternally derived cells, and later on by cells within the embryo as they develop their differentiated phenotype.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7688292     DOI: 10.1210/endo.133.2.7688292

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  25 in total

1.  Characterization and distribution of putative 5-ht7 receptors in guinea-pig brain.

Authors:  Z P To; D W Bonhaus; R M Eglen; L B Jakeman
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

2.  Cell-mediated Delivery and Targeted Erosion of Vascular Endothelial Growth Factor-Crosslinked Hydrogels.

Authors:  Sung Hye Kim; Kristi L Kiick
Journal:  Macromol Rapid Commun       Date:  2010-07-08       Impact factor: 5.734

3.  Expression of the vascular endothelial growth factor receptor, KDR, in human placenta.

Authors:  M Vuckovic; J Ponting; B I Terman; V Niketic; M W Seif; S Kumar
Journal:  J Anat       Date:  1996-04       Impact factor: 2.610

4.  Enhanced expression of vascular endothelial growth factor in lungs of newborn infants with congenital diaphragmatic hernia and pulmonary hypertension.

Authors:  S M Shehata; W J Mooi; T Okazaki; I El-Banna; H S Sharma; D Tibboel
Journal:  Thorax       Date:  1999-05       Impact factor: 9.139

5.  The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade.

Authors:  T Davis-Smyth; H Chen; J Park; L G Presta; N Ferrara
Journal:  EMBO J       Date:  1996-09-16       Impact factor: 11.598

6.  Exogenous vascular endothelial growth factor induces malformed and hyperfused vessels during embryonic neovascularization.

Authors:  C J Drake; C D Little
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

7.  Induction of vascular endothelial growth factor expression by prostaglandin E2 and E1 in osteoblasts.

Authors:  S Harada; J A Nagy; K A Sullivan; K A Thomas; N Endo; G A Rodan; S B Rodan
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

8.  Study protocol: safety and efficacy of propranolol in newborns with Retinopathy of Prematurity (PROP-ROP): ISRCTN18523491.

Authors:  Luca Filippi; Giacomo Cavallaro; Patrizio Fiorini; Marta Daniotti; Valentina Benedetti; Gloria Cristofori; Gabriella Araimo; Luca Ramenghi; Agostino La Torre; Pina Fortunato; Liliana Pollazzi; Giancarlo la Marca; Sabrina Malvagia; Paola Bagnoli; Chiara Ristori; Massimo Dal Monte; Anna Rita Bilia; Benedetta Isacchi; Sandra Furlanetto; Francesca Tinelli; Giovanni Cioni; Gianpaolo Donzelli; Silvia Osnaghi; Fabio Mosca
Journal:  BMC Pediatr       Date:  2010-11-18       Impact factor: 2.125

9.  The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF.

Authors:  J E Park; G A Keller; N Ferrara
Journal:  Mol Biol Cell       Date:  1993-12       Impact factor: 4.138

10.  Patterns of brain angiogenesis after vascular endothelial growth factor administration in vitro and in vivo.

Authors:  J M Rosenstein; N Mani; W F Silverman; J M Krum
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.